Clinical Trial Detail

NCT ID NCT02729961
Title Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Washington
Indications

anaplastic large cell lymphoma

Therapies

Brentuximab vedotin + Ceritinib

Age Groups: adult child

Additional content available in CKB BOOST